In the prior competitive renewal of this grant we proposed an experimental plan of three specific aims, to understand the structure-function relationships of thrombopoietin (TPO), identify genes responsible for MK development and to understand the molecular mechanisms that underlie endomitosis (EnM). We have made much progress in pursuit of these aims, and plan to build upon these advances in the continuing studies proposed herein. Specifically, we plan to A) study the mechanisms that regulate thrombopoiesis and the blood levels of TPO in inflammatory conditions, testing two hypotheses positing that inflammatory stimuli either 1) directly affect TPO gene transcription, mRNA stability or its efficiency of translation or 2) affect TPO blood levels indirectly by altering expression of the TPO receptor, c-mpl; B) determine the intramolecular pathways employed by TPO that transmit signals for MK survival, proliferation and differentiation, focusing on the targets of phosphoinositol-3 kinase, the mechanisms by which cell adhesion play a role in megakaryopoiesis and potential signaling roles for molecules recently determined to bind to the cytoplasmic domain of c-Mpl; C) study both the initiation and maintenance events responsible for EnM, testing the role of survivin, INCENP and Aurora kinases, and the integrity of the late anaphase checkpoint in polyploid MKs. Finally, as we recently participated in the cloning and initial characterization of a new cytokine, a fourth specific aim has been added to D) study the intracellular signaling pathways employed by interleukin (IL)-21 and its corresponding receptor. A major reason to study the signaling of this cytokine is that it provides an opportunity to explore the mechanisms by which related cytokines (IL-2, IL-15 and IL-21) employ seemingly identical initial signal transduction pathways but generate specific downstream events to induce distinct physiologic effects.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Mufson, R Allan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
Internal Medicine/Medicine
Schools of Medicine
La Jolla
United States
Zip Code
Hitchcock, Ian S; Chen, Maximus M; King, Jennifer R et al. (2008) YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood 112:2222-31
Barroga, Charlene F; Pham, Hang; Kaushansky, Kenneth (2008) Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression. Exp Hematol 36:1585-92
Yoshida, Kozue; Kirito, Keita; Yongzhen, Hu et al. (2008) Thrombopoietin (TPO) regulates HIF-1alpha levels through generation of mitochondrial reactive oxygen species. Int J Hematol 88:43-51
Nakao, Takafumi; Geddis, Amy E; Fox, Norma E et al. (2008) PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7:257-66
Kaushansky, Kenneth (2008) Historical review: megakaryopoiesis and thrombopoiesis. Blood 111:981-6
McIntosh, Bryan; Kaushansky, Kenneth (2008) Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol 36:799-806
Chanprasert, Supantitra; Geddis, Amy E; Barroga, Charlene et al. (2006) Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes. Cell Signal 18:1212-8
Kaushansky, Kenneth (2006) Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. Cytokine Growth Factor Rev 17:423-30
Geddis, Amy E; Fox, Norma E; Kaushansky, Kenneth (2006) The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin levels. Exp Hematol 34:82-6
Coleman, Thomas R; Westenfelder, Christof; Togel, Florian E et al. (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 103:5965-70

Showing the most recent 10 out of 93 publications